Domain-Swap Dimerization of Acanthamoeba castellanii CYP51 and a Unique Mechanism of Inactivation by Isavuconazole

Detalhes bibliográficos
Autor(a) principal: Sharma, Vandna
Data de Publicação: 2020
Outros Autores: Shing, Brian, Hernandez-Alvarez, Lilian [UNESP], Debnath, Anjan, Podust, Larissa M.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.1124/molpharm.120.000092
http://hdl.handle.net/11449/208993
Resumo: Cytochromes P450 (P450, CYP) metabolize a wide variety of endogenous and exogenous lipophilic molecules, including most drugs. Sterol 14 alpha-demethylase (CYP51) is a target for antifungal drugs known as conazoles. Using X-ray crystallography, we have discovered a domain-swap homodimerization mode in CYP51 from a human pathogen, Acanthamoeba castellanii CYP51 (AcCYP51). Recombinant AcCYP51 with a truncated transmembrane helix was purified as a heterogeneous mixture corresponding to the dimer and monomer units. Spectral analyses of these two populations have shown that the CO-bound ferrous form of the dimeric protein absorbed at 448 nm (catalytically competent form), whereas the monomeric form absorbed at 420 nm (catalytically incompetent form). AcCYP51 dimerized head-to-head via N-termini swapping, resulting in formation of a nonplanar protein-protein interface exceeding 2000 angstrom 2 with a total solvation energy gain of -35.4 kcal/mol. In the dimer, the protomers faced each other through the F and G a-helices, thus blocking the substrate access channel. In the presence of the drugs clotrimazole and isavuconazole, the AcCYP51 drug complexes crystallized as monomers. Although clotrimazole-bound AcCYP51 adopted a typical CYP monomer structure, isavuconazole-bound AcCYP51 failed to refold 74 N-terminal residues. The failure of AcCYP51 to fully refold upon inhibitor binding in vivo would cause an irreversible loss of a structurally aberrant enzyme through proteolytic degradation. This assumption explains the superior potency of isavuconazole against A. castellanii. The dimerization mode observed in this work is compatible with membrane association and may be relevant to other members of the CYP family of biologic, medical, and pharmacological importance. SIGNIFICANCE STATEMENT We investigated the mechanism of action of antifungal drugs in the human pathogen Acanthamoeba castellanii. We discovered that the enzyme target [Acanthamoeba castellanii sterol 14 alpha-demethylase (AcCYP51)] formed a dimer via an N-termini swap, whereas drug-bound AcCYP51 was monomeric. In the AcCYP51-isavuconazole complex, the protein target failed to refold 74 N-terminal residues, suggesting a fundamentally different mechanism of AcCYP51 inactivation than only blocking the active site. Proteolytic degradation of a structurally aberrant enzyme would explain the superior potency of isavuconazole against A. castellanii.
id UNSP_c23d7b79a959c89b88b0c347ef492685
oai_identifier_str oai:repositorio.unesp.br:11449/208993
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Domain-Swap Dimerization of Acanthamoeba castellanii CYP51 and a Unique Mechanism of Inactivation by IsavuconazoleCytochromes P450 (P450, CYP) metabolize a wide variety of endogenous and exogenous lipophilic molecules, including most drugs. Sterol 14 alpha-demethylase (CYP51) is a target for antifungal drugs known as conazoles. Using X-ray crystallography, we have discovered a domain-swap homodimerization mode in CYP51 from a human pathogen, Acanthamoeba castellanii CYP51 (AcCYP51). Recombinant AcCYP51 with a truncated transmembrane helix was purified as a heterogeneous mixture corresponding to the dimer and monomer units. Spectral analyses of these two populations have shown that the CO-bound ferrous form of the dimeric protein absorbed at 448 nm (catalytically competent form), whereas the monomeric form absorbed at 420 nm (catalytically incompetent form). AcCYP51 dimerized head-to-head via N-termini swapping, resulting in formation of a nonplanar protein-protein interface exceeding 2000 angstrom 2 with a total solvation energy gain of -35.4 kcal/mol. In the dimer, the protomers faced each other through the F and G a-helices, thus blocking the substrate access channel. In the presence of the drugs clotrimazole and isavuconazole, the AcCYP51 drug complexes crystallized as monomers. Although clotrimazole-bound AcCYP51 adopted a typical CYP monomer structure, isavuconazole-bound AcCYP51 failed to refold 74 N-terminal residues. The failure of AcCYP51 to fully refold upon inhibitor binding in vivo would cause an irreversible loss of a structurally aberrant enzyme through proteolytic degradation. This assumption explains the superior potency of isavuconazole against A. castellanii. The dimerization mode observed in this work is compatible with membrane association and may be relevant to other members of the CYP family of biologic, medical, and pharmacological importance. SIGNIFICANCE STATEMENT We investigated the mechanism of action of antifungal drugs in the human pathogen Acanthamoeba castellanii. We discovered that the enzyme target [Acanthamoeba castellanii sterol 14 alpha-demethylase (AcCYP51)] formed a dimer via an N-termini swap, whereas drug-bound AcCYP51 was monomeric. In the AcCYP51-isavuconazole complex, the protein target failed to refold 74 N-terminal residues, suggesting a fundamentally different mechanism of AcCYP51 inactivation than only blocking the active site. Proteolytic degradation of a structurally aberrant enzyme would explain the superior potency of isavuconazole against A. castellanii.University of California San DiegoUniversity of California San Diego Center for Tropical Diseases fundUniversity of California San Diego Academic Senate grantNational Institutes of Health National Center for Advancing Translational SciencesNational Institute of Allergy and Infectious DiseasesFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Department of Energy (DOE) Office of Science User FacilityUniv Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, Ctr Discovery & Innovat Parasit Dis, La Jolla, CA 92093 USAUniv Estadual Paulista, Inst Biociencias Letras & Ciencias Exatas, Dept Fis, Sao Paulo, BrazilUniv Estadual Paulista, Inst Biociencias Letras & Ciencias Exatas, Dept Fis, Sao Paulo, BrazilNational Institutes of Health National Center for Advancing Translational Sciences: 1KL2-TR001444National Institute of Allergy and Infectious Diseases: R21 AI133394National Institute of Allergy and Infectious Diseases: R21 AI141210National Institute of Allergy and Infectious Diseases: R21 AI146460FAPESP: 2018/25311-2Department of Energy (DOE) Office of Science User Facility: DE-AC02-05CH11231Amer Soc Pharmacology Experimental TherapeuticsUniv Calif San DiegoUniversidade Estadual Paulista (Unesp)Sharma, VandnaShing, BrianHernandez-Alvarez, Lilian [UNESP]Debnath, AnjanPodust, Larissa M.2021-06-25T11:45:18Z2021-06-25T11:45:18Z2020-12-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article770-780http://dx.doi.org/10.1124/molpharm.120.000092Molecular Pharmacology. Bethesda: Amer Soc Pharmacology Experimental Therapeutics, v. 98, n. 6, p. 770-780, 2020.0026-895Xhttp://hdl.handle.net/11449/20899310.1124/molpharm.120.000092WOS:000596844800009Web of Sciencereponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengMolecular Pharmacologyinfo:eu-repo/semantics/openAccess2021-10-23T19:23:27Zoai:repositorio.unesp.br:11449/208993Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestrepositoriounesp@unesp.bropendoar:29462021-10-23T19:23:27Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Domain-Swap Dimerization of Acanthamoeba castellanii CYP51 and a Unique Mechanism of Inactivation by Isavuconazole
title Domain-Swap Dimerization of Acanthamoeba castellanii CYP51 and a Unique Mechanism of Inactivation by Isavuconazole
spellingShingle Domain-Swap Dimerization of Acanthamoeba castellanii CYP51 and a Unique Mechanism of Inactivation by Isavuconazole
Sharma, Vandna
title_short Domain-Swap Dimerization of Acanthamoeba castellanii CYP51 and a Unique Mechanism of Inactivation by Isavuconazole
title_full Domain-Swap Dimerization of Acanthamoeba castellanii CYP51 and a Unique Mechanism of Inactivation by Isavuconazole
title_fullStr Domain-Swap Dimerization of Acanthamoeba castellanii CYP51 and a Unique Mechanism of Inactivation by Isavuconazole
title_full_unstemmed Domain-Swap Dimerization of Acanthamoeba castellanii CYP51 and a Unique Mechanism of Inactivation by Isavuconazole
title_sort Domain-Swap Dimerization of Acanthamoeba castellanii CYP51 and a Unique Mechanism of Inactivation by Isavuconazole
author Sharma, Vandna
author_facet Sharma, Vandna
Shing, Brian
Hernandez-Alvarez, Lilian [UNESP]
Debnath, Anjan
Podust, Larissa M.
author_role author
author2 Shing, Brian
Hernandez-Alvarez, Lilian [UNESP]
Debnath, Anjan
Podust, Larissa M.
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Univ Calif San Diego
Universidade Estadual Paulista (Unesp)
dc.contributor.author.fl_str_mv Sharma, Vandna
Shing, Brian
Hernandez-Alvarez, Lilian [UNESP]
Debnath, Anjan
Podust, Larissa M.
description Cytochromes P450 (P450, CYP) metabolize a wide variety of endogenous and exogenous lipophilic molecules, including most drugs. Sterol 14 alpha-demethylase (CYP51) is a target for antifungal drugs known as conazoles. Using X-ray crystallography, we have discovered a domain-swap homodimerization mode in CYP51 from a human pathogen, Acanthamoeba castellanii CYP51 (AcCYP51). Recombinant AcCYP51 with a truncated transmembrane helix was purified as a heterogeneous mixture corresponding to the dimer and monomer units. Spectral analyses of these two populations have shown that the CO-bound ferrous form of the dimeric protein absorbed at 448 nm (catalytically competent form), whereas the monomeric form absorbed at 420 nm (catalytically incompetent form). AcCYP51 dimerized head-to-head via N-termini swapping, resulting in formation of a nonplanar protein-protein interface exceeding 2000 angstrom 2 with a total solvation energy gain of -35.4 kcal/mol. In the dimer, the protomers faced each other through the F and G a-helices, thus blocking the substrate access channel. In the presence of the drugs clotrimazole and isavuconazole, the AcCYP51 drug complexes crystallized as monomers. Although clotrimazole-bound AcCYP51 adopted a typical CYP monomer structure, isavuconazole-bound AcCYP51 failed to refold 74 N-terminal residues. The failure of AcCYP51 to fully refold upon inhibitor binding in vivo would cause an irreversible loss of a structurally aberrant enzyme through proteolytic degradation. This assumption explains the superior potency of isavuconazole against A. castellanii. The dimerization mode observed in this work is compatible with membrane association and may be relevant to other members of the CYP family of biologic, medical, and pharmacological importance. SIGNIFICANCE STATEMENT We investigated the mechanism of action of antifungal drugs in the human pathogen Acanthamoeba castellanii. We discovered that the enzyme target [Acanthamoeba castellanii sterol 14 alpha-demethylase (AcCYP51)] formed a dimer via an N-termini swap, whereas drug-bound AcCYP51 was monomeric. In the AcCYP51-isavuconazole complex, the protein target failed to refold 74 N-terminal residues, suggesting a fundamentally different mechanism of AcCYP51 inactivation than only blocking the active site. Proteolytic degradation of a structurally aberrant enzyme would explain the superior potency of isavuconazole against A. castellanii.
publishDate 2020
dc.date.none.fl_str_mv 2020-12-01
2021-06-25T11:45:18Z
2021-06-25T11:45:18Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1124/molpharm.120.000092
Molecular Pharmacology. Bethesda: Amer Soc Pharmacology Experimental Therapeutics, v. 98, n. 6, p. 770-780, 2020.
0026-895X
http://hdl.handle.net/11449/208993
10.1124/molpharm.120.000092
WOS:000596844800009
url http://dx.doi.org/10.1124/molpharm.120.000092
http://hdl.handle.net/11449/208993
identifier_str_mv Molecular Pharmacology. Bethesda: Amer Soc Pharmacology Experimental Therapeutics, v. 98, n. 6, p. 770-780, 2020.
0026-895X
10.1124/molpharm.120.000092
WOS:000596844800009
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Molecular Pharmacology
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 770-780
dc.publisher.none.fl_str_mv Amer Soc Pharmacology Experimental Therapeutics
publisher.none.fl_str_mv Amer Soc Pharmacology Experimental Therapeutics
dc.source.none.fl_str_mv Web of Science
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv repositoriounesp@unesp.br
_version_ 1826303551827083264